Differential impact of immune escape mutations G145R and P120T on the replication of lamivudine-resistant hepatitis B Virus e antigen-positive and -negative strains

Journal of Virology

Volumn 84, Issue 2, 2010, Pages 1026-1033

  Amini Bavil Olyaee, Samad ^a   Vucur, Mihael ^a   Luedde, Tom ^a   Trautwein, Christian ^a   Tacke, Frank ^a  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; HEPATITIS B(E) ANTIGEN; HEPATITIS E ANTIGEN; LAMIVUDINE; TENOFOVIR;

ANTIVIRAL SUSCEPTIBILITY; ARTICLE; CONTROLLED STUDY; DRUG SENSITIVITY; GENE MUTATION; GENETIC VARIABILITY; HEPATITIS B VIRUS; MOLECULAR CLONING; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; VIRUS REPLICATION; VIRUS RESISTANCE; VIRUS STRAIN;

ANTIVIRAL AGENTS; CELL LINE, TUMOR; DRUG RESISTANCE, VIRAL; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HUMANS; LAMIVUDINE; MICROBIAL SENSITIVITY TESTS; MUTATION; TRANSFECTION; VIRAL ENVELOPE PROTEINS; VIRUS REPLICATION;

HEPATITIS B VIRUS;

EID: 73849096150     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.01796-09     Document Type: Article

References (34)

1. Amini-Bavil-Olyaee, S., U. Herbers, S. R. Mohebbi, F. Sabahi, M. R. Zali, T. Luedde, C. Trautwein, and F. Tacke. 2009. Prevalence, viral replication efficiency and antiviral drug susceptibility of rtQ215 polymerase mutations within the hepatitis B virus genome. J. Hepatol. 51:647-654.
2. Amini-Bavil-Olyaee, S., U. Herbers, J. Sheldon, T. Luedde, C. Trautwein, and F. Tacke. 2009. The rtA194T polymerase mutation impacts viral replication and susceptibility to tenofovir in hepatitis B e antigen-positive and hepatitis B e antigen-negative hepatitis B virus strains. Hepatology 49:1158-1165.
3. Bock, C. T., B. Buerke, H. L. Tillmann, F. Tacke, V. Kliem, M. P. Manns, and C. Trautwein. 2003. Relevance of hepatitis B core gene deletions in patients after kidney transplantation. Gastroenterology 124:1809-1820.
4. Bock, C. T., H. L. Tillmann, J. Torresi, J. Klempnauer, S. Locarnini, M. P. Manns, and C. Trautwein. 2002. Selection of hepatitis B virus polymerase mutants with enhanced replication by lamivudine treatment after liver transplantation. Gastroenterology 122:264-273.
5. Brunetto, M. R., F. Oliveri, B. Coco, G. Leandro, P. Colombatto, J. M. Gorin, and F. Bonino. 2002. Outcome of anti-HBe positive chronic hepatitis B in alpha-interferon treated and untreated patients: a long term cohort study. J. Hepatol. 36:263-270.
6. Chen, R. Y., R. Edwards, T. Shaw, D. Colledge, W. E. Delaney, H. Isom, S. Bowden, P. Desmond, and S. A. Locarnini. 2003. Effect of the G1896A precore mutation on drug sensitivity and replication yield of lamivudine-resistant HBV in vitro. Hepatology 37:27-35.
7. Datta, S., R. Panigrahi, A. Biswas, P. K. Chandra, A. Banerjee, P. K. Mahapatra, C. K. Panda, S. Chakrabarti, S. K. Bhattacharya, K. Biswas, and R. Chakravarty. 2009. Genetic characterization of hepatitis B virus in peripheral blood leukocytes: evidence for selection and compartmentalization of viral variants with immune escape G145R mutation. J. Virol. 83: 9983-9992.
8. Dienstag, J. L. 2009. Benefits and risks of nucleoside analog therapy for hepatitis B. Hepatology 49:S112-S121.
9. Di Marco, V., and A. Craxi. 2009. Chronic hepatitis B: who to treat and which choice of treatment? Expert Rev. Anti. Infect. Ther. 7:281-291.
10. European Association for the Study of the Liver. 2009. EASL clinical practice guidelines: management of chronic hepatitis B. J. Hepatol. 50:227-242.
11. Funk, M. L., D. M. Rosenberg, and A. S. Lok. 2002. World-wide epidemiology of HBeAg-negative chronic hepatitis B and associated precore and core promoter variants. J. Viral Hepat. 9:52-61.
12. Hadziyannis, S. J., and D. Vassilopoulos. 2001. Hepatitis B e antigen-negative chronic hepatitis B. Hepatology 34:617-624.
13. Hawkins, A. E., R. J. Gilson, N. Gilbert, T. G. Wreghitt, J. J. Gray, I. Ahlers-de Boer, R. S. Tedder, and G. J. Alexander. 1996. Hepatitis B virus surface mutations associated with infection after liver transplantation. J. Hepatol. 24:8-14.
14. Henke-Gendo, C., S. Amini-Bavil-Olyaee, D. Challapalli, C. Trautwein, H. Deppe, T. F. Schulz, A. Heim, and F. Tacke. 2008. Symptomatic hepatitis B reactivation despite reduced viral fitness is associated with HBV test and immune escape mutations in an HIV-coinfected patient. J. Infect. Dis. 198: 1620-1624.
15. Jammeh, S., H. C. Thomas, and P. Karayiannis. 2007. Replicative competence of the T131I, K141E, and G145R surface variants of hepatitis B virus. J. Infect. Dis. 196:1010-1013.
16. Kalinina, T., A. Iwanski, H. Will, and M. Sterneck. 2003. Deficiency in virion secretion and decreased stability of the hepatitis B virus immune escape mutant G145R. Hepatology 38:1274-1281.
17. Karlmark, K. R., R. Weiskirchen, H. W. Zimmermann, N. Gassler, F. Ginhoux, C. Weber, M. Merad, T. Luedde, C. Trautwein, and F. Tacke. 2009. Hepatic recruitment of the inflammatory Gr1+ monocyte subset upon liver injury promotes hepatic fibrosis. Hepatology 50:261-274.
18. Marcellin, P., E. J. Heathcote, M. Buti, E. Gane, R. A. de Man, Z. Krastev, G. Germanidis, S. S. Lee, R. Flisiak, K. Kaita, M. Manns, I. Kotzev, K. Tchernev, P. Buggisch, F. Weilert, O. O. Kurdas, M. L. Shiffman, H. Trinh, M. K. Washington, J. Sorbel, J. Anderson, A. Snow-Lampart, E. Mondou, J. Quinn, and F. Rousseau. 2008. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N. Engl. J. Med. 359:2442-2455.
19. Michitaka, K., F. Akbar, and M. Onji. 2007. Prevention of hepatitis B virus infection by vaccination: progress and problems. Hepatol. Res. 37:673-675.
20. Sheldon, J., and V. Soriano. 2008. Hepatitis B virus escape mutants induced by antiviral therapy. J. Antimicrob. Chemother. 61:766-768.
21. Sloan, R. D., S. Ijaz, P. L. Moore, T. J. Harrison, C. G. Teo, and R. S. Tedder. 2008. Antiviral resistance mutations potentiate hepatitis B virus immune evasion through disruption of its surface antigen a determinant. Antivir. Ther. 13:439-447.
22. Sorrell, M. F., E. A. Belongia, J. Costa, I. F. Gareen, J. L. Grem, J. M. Inadomi, E. R. Kern, J. A. McHugh, G. M. Petersen, M. F. Rein, D. B. Strader, and H. T. Trotter. 2009. National Institutes of Health consensus development conference statement: management of hepatitis B. Hepatology 49:S4-S12.
23. Tabor, E. 2006. Infections by hepatitis B surface antigen gene mutants in Europe and North America. J. Med. Virol. 78(Suppl. 1):S43-S47.
24. Tacke, F., C. Gehrke, T. Luedde, A. Heim, M. P. Manns, and C. Trautwein. 2004. Basal core promoter and precore mutations in the hepatitis B virus genome enhance replication efficacy of lamivudine-resistant mutants. J. Virol. 78:8524-8535.
25. Tacke, F., C. Liedtke, S. Bocklage, M. P. Manns, and C. Trautwein. 2005. CREB/PKA sensitive signalling pathways activate and maintain expression levels of the hepatitis B virus pre-S2/S promoter. Gut 54:1309-1317.
26. Tacke, F., M. P. Manns, and C. Trautwein. 2004. Influence of mutations in the hepatitis B virus genome on virus replication and drug resistance-implications for novel antiviral strategies. Curr. Med. Chem. 11:2667-2777.
27. Tenney, D. J., R. E. Rose, C. J. Baldick, K. A. Pokornowski, B. J. Eggers, J. Fang, M. J. Wichroski, D. Xu, J. Yang, R. B. Wilber, and R. J. Colonno. 2009. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy. Hepatology 49:1503-1514.
28. Tian, Y., Y. Xu, Z. Zhang, Z. Meng, L. Qin, M. Lu, and D. Yang. 2007. The amino acid residues at positions 120 to 123 are crucial for the antigenicity of hepatitis B surface antigen. J. Clin. Microbiol. 45:2971-2978.
29. Torresi, J. 2002. The virological and clinical significance of mutations in the overlapping envelope and polymerase genes of hepatitis B virus. J. Clin. Virol. 25:97-106.
30. Torresi, J., L. Earnest-Silveira, G. Civitico, T. E. Walters, S. R. Lewin, J. Fyfe, S. A. Locarnini, M. Manns, C. Trautwein, and T. C. Bock. 2002. Restoration of replication phenotype of lamivudine-resistant hepatitis B virus mutants by compensatory changes in the "fingers" subdomain of the viral polymerase selected as a consequence of mutations in the overlapping S gene. Virology 299:88-99.
31. Torresi, J., L. Earnest-Silveira, G. Deliyannis, K. Edgtton, H. Zhuang, S. A. Locarnini, J. Fyfe, T. Sozzi, and D. C. Jackson. 2002. Reduced antigenicity of the hepatitis B virus HBsAg protein arising as a consequence of sequence changes in the overlapping polymerase gene that are selected by lamivudine therapy. Virology 293:305-313.
32. Trautwein, C. 2004. Mechanisms of hepatitis B virus graft reinfection and graft damage after liver transplantation. J. Hepatol. 41:362-369.
33. Villet, S., G. Billioud, C. Pichoud, J. Lucifora, O. Hantz, C. Sureau, P. Deny, and F. Zoulim. 2009. In vitro characterization of viral fitness of therapyresistant hepatitis B variants. Gastroenterology 136:168-176.
34. Weber, B. 2005. Genetic variability of the S gene of hepatitis B virus: clinical and diagnostic impact. J. Clin. Virol. 32:102-112.